Stacked ensemble learning and in-silico profiling reveal dual DPP-IV and SGLT2 inhibitors from Moringa oleifera metabolites
Abstract
Diabetes mellitus (DM) is a growing global health challenge, particularly in low-resource settings where access to effective therapies remains limited. Dual inhibition of dipeptidyl peptidase IV (DPP-IV) and sodium-glucose co-transporter 2 (SGLT2) offers a synergistic therapeutic strategy by enhancing insulin secretion and promoting glucose excretion. This study developed an integrated in silico framework combining stacked ensemble machine learning, molecular docking, MD Simulations, and ADMET profiling to identify dual DPP-IV/SGLT2 inhibitors from M. oleifera metabolites. Baseline models were generated using 110 algorithm-descriptor combinations per target, and stacking significantly improved predictive accuracy, achieving Matthews Correlation Coefficients of 0.968 (training) and 0.937 (testing) for DPP-IV and 0.968 (training) and 0.861 (testing) for SGLT2. Validation against FDA-approved inhibitors confirmed the models' reliability and generalisability. LC-MS/MS profiling of M. oleifera revealed several metabolites with high predicted activity, among which vitexin, homoorientin, lariciresinol 4-O-β-D-glucopyranoside, and N,α-L-rhamnopyranosyl vincosamide showed strong binding affinities and favourable pharmacokinetic properties. MD Simulations analyses further position N,α-L-rhamnopyranosyl vincosamide as a potential dual DPP-IV/SGLT2 hit inhibitor. The findings highlight M. oleifera as a promising source of multitarget antidiabetic compounds and demonstrate the potential…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.